Feeds:
Posts
Comments

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

May 1, 2017 by 2012pharmaceutical

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017  BOSTON, MA • UNITED STATES

Reporter: Aviva Lev-Ari, PhD, RN

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover the event in

REAL TIME

Aviva Lev-Ari, PhD, RN will be streaming live from the floor of the Westin Hotel in Boston on May 1-3, 2017

@pharma_BI

@AVIVA1950

#WMIF17

Forthcoming SEVEN e-Books in 2017 AND Eight e-Books on Amazon.com

https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/

 

Biggest Voices in Cardiovascular Care

2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston

https://worldmedicalinnovation.org/agenda/

 

Monday, May 1, 2017

7:00 am – 8:00 am
Lilly Foyer
Registration and Breakfast
8:00 am – 11:30 am
Pfizer Ballroom
First Look: The Next Wave of Cardiology Breakthroughs

Harvard Medical School investigators describe their most promising work in rapid fire presentations highlighting commercial opportunities in cardiovascular and cardiometabolic care. Nineteen rising stars from Brigham and Women’s Hospital and Massachusetts General Hospital will present in 10-minute sessions.

For a full look at speakers and presentations, please visit the Highlight’s page.

Early career Harvard Medical School investigators kick-off the World Medical Innovation Forum with rapid fire presentations of their high potential new technologies. Nineteen rising stars from Brigham Health and Massachusetts General Hospital will highlight in ten-minute presentations their discoveries and insights that will be the disruptive cardiovascular care of the future. This session is designed for investors, leaders, donors, entrepreneurs and investigators and others who share a passion for identifying emerging high-impact technologies. The top presenter each from BWH and MGH will be awarded the Austen-Braunwald Innovation Prize on Day 2 of the Forum. The prize carries a $10,000 award.

Novel Target Discovery Pipeline for Calcific Aortic Valve Disease
Elena Aikawa, MD, PhD
Director, Heart Valve Translational Research Program, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School

  • Aortic stenosis is a progress of Calcific Aortic Valve Disease (CAVD) – 80,000 patients – sole solution is surgery
  • Imaging methods for visualization of microcalcification formation: MRI, PET/CT, CAVD Gene network, proteomics heat mapNIRF imaging, microdissection, histology, Tissue layers cells
  • Serum Sortilin associated with aortic calcification and CVD risk
  • Discovery pipeline and CAVD Mapping

A zebrafish pipeline for cardiovascular precision medicine
Manu Beerens, PhD
Postdoctoral Research Fellow, Brigham and Women’s Hospital; Harvard Medical School

  • Cardiomyopathy – group of cardiac disorders: CHF, Atherosclerosis, metabolic syndrome, AF
  • Zebrafish at the forefront of CVD Precision Medicine
  • Luciferase activity vs ttn
  • high throughput screening to identify naxos modifiers
  • Endpoints: BNP levels Cardiac contractility

Using zebrafish to understand and harness cardiac regeneration

Caroline Burns, PhD
Associate Biologist, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School

  • Heart regeneration
  • Regenerative hearts vs Non-Regenerative hearts
  • How cardiomyocytes proliferation induced following injury
  • Uninjured, 1 day after, 7 days after,
  • Failure to regenerate is related to failure of myoocardial proliferation
  • Genetic factors required for myocardial proliferation
  • myocardial proliferation – by Chromatin – mononuclear >4c ploidy
  • Mononuclear in Human Heart – as research target
  • How to promote myocardial proliferation
  • Small molecule as enhanced to drive proliferation

Bioactive Lipid Profiling Can Identify Potential Targets for Altering Life Course Trajectories Toward Cardiometabolic Disease
Susan Cheng, MD
Associate Physician, Brigham and Women’s Hospital, Partners HealthCare; Assistant Professor, Harvard Medical School

  • Bioactive Lipids
  • Endogenous and exhaugenous factors
  • Biochemical intermediates
  • mechanisms
  • health and disease outcomes
  • Small lipid Mediators of Upstream: Eicosanoids and Incidence of Diabetes as Targets for Present and Future
  • cardiometabolic risk in future early vs late prediabetes, and DM
  • shared pathways
  • Statins favoral response
  • Stree or Injury
  • Linoleic Acid
  • Disease and Phynotyping specific investigations
  • dosing

 

Small Molecule Predictors of Outcome After Cardiac Interventions
Sammy Elmariah, MD
Assistant in Medicine, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School

  • Valvular heart disease – elderly, Aortic valve stenosis leads to failure of compensatory ventricular activity of dysfunction
  • small molecule
  • fiadnostics biomarkers
  • Acute kidney injury due to metabolite, adenohomosestine
  • validate the model – after METABOLITE data is added to the risk classification
  • Personalizing the timing of Valve Intervention
  • Biomarkers in blood predicts systolic function, EF,
  • Metabolite-Driven clinical trial of Aortic stenosis
  • TAVR

Translational trials in microRNAs
Mark Feinberg, MD
Physician, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School

  • non-coding RNA Biologics – 98% of the genome
  • 2% are coding
  • MiRNA therapeutics for Atherosclerosis
  • MiRNA – Replacement Therapy- ApoE-?-NGL
  • Cholesterol, LDL
  • Vascular endothelium: Inflammation, HF, Diabetic wound healing – tissue thickness
  • Example: IncRNA, Example3: miR-26a – BMP-SMAD1-ID1-p21
  • 3 platforms for targeting non-coding RNAs in CVD:
  1. peptide-conjucated nc-RNA
  2. Ab-conjugasted nc-RNA

 

New approaches to controlling stem cell fate
Yick Fong, PhD
Research Scientist, Brigham and Women’s Hospital; Assistant Professor of Medicine, Harvard Medical School

  • controlling Stem cell fate by Transcription Factors
  • Pluripotent, fibroblasts – transformed into Bone, nerve, heart, pancreatic cells
  • This process is randon and inefficient
  • GOAL: Transplantation, drug/therapeutic screens
  • Cellular identity and function
  • In Vitro Reconstruction of cell-type specific Transcription
  • Identify Disease mechanism of Heart disease by mutation that cause disruptionCo-regulators disruption

 

Exercise Prescription to Improve Cardiovascular and Cancer Outcomes in Cancer Survivors
John Groarke, MD
Cardiologist, Brigham and Women’s Hospital; Instructor of Medicine, Harvard Medical

  • cancer survivers have risk for CVD
    Metabolic Equivalent ((METS)
  • METS is the highest to lower CVD in Cancer survivors
  • Onco-cardiac rehabilitation
  • Increase excercise performance vs physical de-conditioned state
  • Cardioprotection to mitigate CV Toxicities of cancer therapy

Personalizing Diabetic Management with Hemoglobin A1c
John Higgins, MD
Associate Pathologist, Massachusetts General Hospital; Associate Professor, Harvard Medical School

  • Non glucose factors that affect A1C
  1. RBC Age span – if circulate live longer accumulates more glucose
  2. AstraZeneca, Eli Lilly, Novo Nordics – ALL conduct clinical trials to lower A1C
  • Personalize DM Management
  • Using existing assays with the RBC Age adjustment — for achieving better future Outcomes
  • Device Manufacturers to adjust the device

Characterizing an Early HeartFailure pulmonary EF (HFpEF) Phenotype: Cardiometabolic Disease and Pulmonary Hypertension
Jennifer Ho, MD
Assistant Physician, Massachusetts General Hospital; Member of the Faculty of Medicine, Harvard Medical School

  • Ejection Frunction in Pulmonary Hypertension (PH)
  • Obesity >–>>> PH recapitulates human HP
  • PAECs – Molecular mechanisms – Pulmonary Artery #Endotheline Cells
  • P13K/Akt (Insulin) — AMPK  (Metformin) –>> eNOS — >> Vasodilation
  • Study ex-vivo PAEC from patients with HFpEF
  1. HFpEF subphenotypes
  2. drug therapy
  3. screening

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
Amit Khera, MD
Cardiologist, Massachusetts General Hospital; Instructor, Harvard Medical School

  • Integration of Genetic data and CVD data
  • GWAS –>> 60 variants associated with coronary risk
  • Polygenic genetic risk score
  • Risk for MI: Genetic risk Interpretation: Monogenic vs Polygenic
  • High risk comes from polygenic risk: Smoking, Obesity, Excercise, Health diet
  • Healthy lifestyle “corrects” genetic factor

Monogenic:

  • Hypercholesterolemia
  • Trycleceride
  • increased lipoproteins _ ASA Lp(a) inhibitors

Polygenic

  • life style, diet excercise
  • medicationS: Statins

A Novel Epigenetic Complex Implicated in Thoracic Aortic Aneurysm (TAA)
Mark Lindsay, MD, PhD
Physician, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

  • Thoracic Aortic Aneurysm
  • Aortic dissection
  • VSCULAR SMOOOTH MUSCLE CELLS in the aorta’s leaves – neo-intima damage vs knockout MALAT1 – nepangiogenesis
  • GENETIC MUTATIONS as Biologic Probes
  • GENE: HDAC9 – BRG1, MALAT1 (RNA) – STRESS in aortic homeostasis
  • Aortic root and Ascending Aorta
  • Elastin and colagen

 

Atrial Fibrillation: Genetic Basis and Clinical Implications
Steven Lubitz, MD
Cardiac Electrophysiologist, Massachusetts General Hospital

  • 6 million in US 34 Million WOrldwide
  • Leading cause of stroke
  • AF is hard to diagnose
  • preventable with anticoagulation
  • AF is Familial and inheritable
  • Genetic Variation associated with AF – genetics stratified risk
  • AF Screening: as Stroke prevention – AliveCor
  • electronic health records are powerful repositories
  • AF genetic risk – as a Biomarker
  • Technologies for screening

Targeting Vascular Calcification to Prevent Cardiovascular Disease
Rajeev Malhotra, MD
Staff Cardiologist, Associate Medical Director of the Cardiac Intensive Care Unit, Associate Director of the Cardiopulmonary Exercise Laboratory, Massachusetts General Hospital; Instructor in Medicine, Harvard Medical School

  • Vascular Classification: Atherocalcification Vascula r disease
  • plaque destabilization
  • coronary and aortic
  • HUMAN GENETICS Studies: GWAS
  1. Genotype
  2. Aortic CT
  3. Identify Potential Genes, increase expression associated with classification
  4. Functional-Mechanical Studies: smooth muscle cell – more proliferative vs more contractile
  5. control vs inhibition
  6. Human model of Vascular classification vs Mouse Model
  7. Disease of Vascular classification: Calxiphylaxis – HEMODialysis patients – >50% mortality within 1 year of diagnosis
  8. Drug development and Clinical Trials

Stratifying Exercise Dysfunction
Bradley Maron, MD
Association Physician, Brigham and Women’s Hospital; Assistant Professor, Harvard Medical School

  • Exercise Dysfunction: Complex Pathophynotype
  • iCPET: O2, exercise capacity, Pulmonary function, Hemodynamics, Invesive cardiac performance,
  • NEW SYSTEM DESIGNED: Network-Based Clinical Risk Calculator by Four Clusters – Network determine cluster assignment
  • Point of care tool – integrate into iCPET
  • Provides insights into HTN, Valvular, Myocaritis, cardiomyopathy
  1. Pulmonary
  2. exercise capacity
  3. ventilation perf
  4. o2 transport
  5. Invasive cardiac

Novel Mouse Models of Remote Cardioprotection
Benjamin Olenchock, MD, PhD
Cardiovascular Medicine Specialist, Brigham and Women’s Hospital; Instructor in Medicine, Harvard Medical School

  • Ischemic Preconditing
  • Remote limb BP Cuff in pig prevented Ischemia in heart
  • Cell death is multi cell types and cell death
  • EGLN – succinate +CO2 – Transciptional Hypoxia responses
  • EGLN Inhibitor: Systemic Egln1 deletion vs Skeletal Muscle Egln1 Deletion – Study of Cardiac Protection
  • Cardioprotective Mediators: Tissue Hypoxia ++>> Altered hepatic Tryptophan Metabolism —>> Cardioprotection
  • Tumor xenograph

Harnessing Endogenous Mechanisms of Programmed Gene Expression for Therapeutic Benefit In Cardiometabolic Disorders
Jorge Plutzky, MD
Director, Preventive Cardiology, Cardiovascular Medicine, Brigham and Women’s Hospital

  • PPARs
  • RXR, RAR – Retinohyde –>> Retinoic Acid
  • Transcription factors: Physiology and Pathology
  • PPARalpha  <<<<—- Lipase, Lipid sustrate
  • Epigenetic Code
  • Histone Readers: Selective Inhibition of Tumor Oncogenes by DIsruption Enhancing ranked by BRD4 signal: Chemotaxis, adhesion, Migration, Thrombosis, Inflammation
  • Atherosclerosis: Knows protein, Unknown protein: Promoters, enhancers

 

Aging and the activin type II receptor pathway: a new target for heart failure therapy?
Jason Roh, MD
Assistant in Medicine, Massachusetts General Hospital; Instructor, Harvard Medical School

  • AGING and CVD – it is part of pathophysiology – CATABOLIC PROCESSES
  • Organ level

muscle waist, atropy –>> impaired function: Hand grip strength, walk speed —->> HF, systolic and diastolic Strain rate

  • Cell level: Isotype Abvs ActRII Ab

contractility, Seen in HF models and HFpEF

  • Activin-A decreases with AGE

Signaling and pulmonary vascular disease – PAH
Paul Yu, MD, PhD
Physician, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School

  • FIBROSIS: TGF
  • OSTEOGENESIS ANTI-APOPTOSIS
  • Activin/TGFBeta —>>> BMP9 (ALK1c)
  • Loss od signaling
  • Inflammation
  • high shear stress
  • PAH
  1. Idiopathic: Sporadic or heritable
  2. Associated PAH: Scleroderma or lupus
  • Dysregulated angiogenesis– Anti VEGF165 – Zr-bevacizumab – Using PET-CT
11:30 am – 11:45 am
Break and Move to Discovery Café Breakout
11:45 am – 1:05 pm
7th Floor
Discovery Café Breakout Sessions: Sharing Perspectives

Seven intensive workshops led by our top faculty will address cutting-edge cardiovascular topics. Seating is reserved at the point of registration. Lunch included.

Topics to be covered include:

  • Cardiac Replacement Therapy: The Next Ten Years
  • Heart Failure: Back in The Game through New Pathways
  • Payment Models: Provider’s Perspective
  • Molecular Imaging: New Biological Endpoints – Function Over Structure
  • Open Innovation in Medical Devices: What is it? What Are the Barriers?
  • Wearables for Cardiovascular Health:  How to Validate and Integrate in Care Paths?
  • Image Based Artificial Intelligence: Which Cardiac Disease Segments and Why?

For a full list of speakers, please visit the Highlight’s page.

Seven intensive workshops led by our top faculty will address cutting-edge cardiovascular topics. Seating is reserved at the point of registration. Lunch included.

Panels

Cardiac Replacement Therapy: The Next Ten Years- Great Republic | 7th Floor

  • Introducer: Seema Basu, PhD, Market Sector Leader, Partners HealthCare
  • Garrick Stewart, MD, Associate Physician, Medical Director, Mechanical Circulatory Support Unit, Brigham and Women’s Hospital; Instructor in Medicine, Harvard Medical School
  • Erin Coglianese, MD, Medical Director, Mechanical Cardiac Support Program, Massachusetts General Hospital

Heart Failure: Back in The Game through New Pathways- Essex North | 3rd Floor

  • Introducer: Dan Castro, Managing Director, Licensing, Partners HealthCare
  • Anju Nohria, MD, Director, Cardio-Oncology Program, Cardiovascular Medicine Specialist, Brigham and Women’s Hospital
  • Christopher Newton-Cheh, MD, Cardiologist, Heart Failure and Transplantation, Massachusetts General Hospital

Payment Models: Provider’s Perspective- North Star | 7th Floor

  • Introducer: Sepideh Hashemi, Market Sector Leader, Partners HealthCare
  • Thomas Gaziano, MD, Associate Physician, Cardiovascular Medicine, Brigham and Women’s Hospital; Assistant Professor, Harvard Medical School
  • Jason Wasfy, MD, Assistant Medical Director, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

Molecular and Advanced Imaging: New Biological Endpoints – Function Over Structure- Baltic | 7th Floor

  • Introducer: Glenn Miller, PhD, Market Sector Leader, Partners HealthCare
  • Marcelo Di Carli, MD, Chief, Division of Nuclear Medicine and Molecular Imaging, Brigham and Women’s Hospital; Professor of Radiology and Medicine, Harvard Medical School
  • Farouc Jaffer, MD, PhD, Director, Coronary Intervention, Cardiac Catheterization Laboratory, Cardiology Division, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
  • Sharmila Dorbala, MD, Director, Nuclear Cardiology, Brigham and Women’s Hospital; Associate Professor of Radiology, Harvard Medical School

Open Innovation in Medical Devices: What is it? What Are the Barriers?- Essex South | 3rd Floor

  • Introducer: Pat Fortune, PhD, Vice President for Market Sectors, Partners HealthCare
  • Elazer Edelman, MD, PhD, Senior Attending Physician, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School; Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology, MIT
  1. Mortality of cardiovascular disease declines as a result of Medical Innovations as Devices
  2. Are innovations tappering off or New ones are coming??
  • Bruce Rosengard, MD, Chief Medical Science and Technology Officer, Johnson & Johnson Medical Devices Companies
  • Ronald Tompkins, MD, Director, Surgery, Innovation & Bioengineering, Massachusetts General Hospital; Sumner M. Redstone Professor of Surgery, Harvard Medical School

ALL

  1. Solution for Heart Failure – low hanging fruit was picked already – a workabke artificial heart more important than another Stent
  2. Large scale Programs better than multiple PI small grant applications, many are not innovating, conflict of interests, Academia and Industry relations
  3. 99% get better with a device but 1% is been harmed
  4. FDA – overworked Underfunded 52 applications reviewed per employee

 

Wearables for Cardiovascular Health:  How to Validate and Integrate in Care Paths?- Parliament/Adams | 7th Floor

  • Introducer: Thomas Aretz, MD, Vice President, Global Programs, Partners HealthCare
  • David Levine, MD, Home Hospital Director, Brigham and Women’s Hospital; Fellow in General Internal Medicine, Harvard Medical School
  • Kamal Jethwani, MD, Senior Director, Connected Health Innovation, Partners HealthCare; Assistant Professor, Dermatology, Harvard Medical School
  • Paolo Bonato, PhD, Director, Motion Analysis Laboratory, Spaulding Hospital; Associate Professor, Harvard Medical School

Image Based Artificial Intelligence: Which Cardiac Disease Segments and Why?  Empire | 7th Floor

  • Introducer: Trung Do, Vice President, Business Development, Partners HealthCare
  • George Washko, MD, Associate Physician, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School
  • Mark Michalski, MD, Director, CCDS, Brigham and Women’s Hospital, Massachusetts General Hospital
 
 
1:05 pm – 1:30 pm
Break
1:30 pm – 1:35 pm
Boston Scientific Ballroom
Opening Remarks Christopher Coburn
Introduction by: Anne Klibanski, MD,
  • Chief Academic Officer, Partners HealthCare
  • Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, Harvard Medical School
David Torchiana, MD
  • CEO, Partners HealthCare
1:35 pm – 1:55 pm
Boston Scientific Ballroom
Reinventing Cardiac Care

Two renowned clinical leaders provide an overview of the medical and economic challenges that cardiovascular and cardiometabolic disorders present.

They will highlight strategic direction in cardiac research and clinical care at Partners, and address how recent trends in investment, regulation, and policy may be dovetailed with efforts at Partners.

The experts also spotlight for attendees the various therapies, diagnostics, devices, and critical issues that will be discussed throughout the upcoming 2.5 days of the World Medical Innovation Forum.

Calum MacRae, MD, PhD
  • Chief of Cardiovascular Medicine, Brigham and Women’s Hospital
  • Associate Professor of Medicine, Harvard Medical School
  1. New drugs: Molecular targets, Monoclonals, alternative to Statins
  2. devices implantable
  3. IT and EMR, BI
  4. Integration of Innovations, Clinical and Translational
Anthony Rosenzweig, MD
  • Chief, Cardiology Division, Massachusetts General Hospital
  • Professor of Medicine, Harvard Medical School
  1. Aging and longevity of CVD Patients will increase the expense on CVD as disease
1:55 pm – 2:45 pm
Boston Scientific Ballroom
CEO Roundtable: Today’s Learning, Tomorrow’s Opportunities

Discussion on contribution of technology innovation to the treatment of cardiovascular disease reflecting on lessons and how they shape investment decisions.

Moderator: Benjamin Pless
  • Executive in Residence, Partners HealthCare Innovation
  1. Electrical physiology: implantable paceamker – first 1958, lead to RV, last 10years th enetire pacemaker implanted in the heart no leads. Surgical TAVR, Implantabke to Mitral valve
John Flannery
  • CEO, GE Healthcare
  1. Healthcare data, Analytics, data integration, machine learning, mapping efficiency,
  2. Data analytics is Present, Devices was the Past
  3. Shorten cycle of learning
Michael Minogue
  • CEO, Abiomed
  1. 20X of revenue growth since 2010
  2. HEART PUMP – only FDA approached for recover the heart, pump blood out of the heart
  3. Tracking ALL patients not samples – ALL Outcomes, all patients
  4. HF – 24×7 employees of Abiomed in labs in Hospitals, 5 years after heart attack, another attack 30% dies
  5. Protocol and standards
Michael Mussallem
  • CEO, Edwards Lifesciences
  1. TAVR device no need for open heart surgery
  2. Selling services – heart-lung machine: Perfusion is a product and Service
  3. Structural heart disease – multiple innovations
Timothy Ring
  • CEO, Bard
  1. Oncology, Vascular, Urology, PDA
  2. Business model failure – clinical economic point of view
  3. Start up community and acquisitions – platforms for further investments
Lewis Sandy, MD
  • EVP, Clinical Advancement, UnitedHealth Group – Payer’s perspective
  1. Health Benefits
  2. Optum – Data to improve care,
  3. 30% of cost of care is WASTE, eliminate this cost item
  4. Heart transfer: Innvation cycle
  5. Collaboration with Pharma and with Devices: Data Analytics – fee for service vs Value Model – Total cost may be less
2:45 pm – 3:35 pm
Boston Scientific Ballroom
Tackling the AFib Epidemic

Evolving trends in diagnosis, prevention, and treatment of atrial fibrillation. Factors that will influence patient care over the next 5 years are considered, including risk stratification, procedure and technology options, and potential implications of CMS policies, such as bundling.

 

Moderator: Jagmeet Singh, MD, DPhil
  • Associate Chief, Cardiology Division, Massachusetts General Hospital Heart Center
  • Professor of Medicine, Harvard Medical School
  1. HF treated by five drugs
  2. 3Million Patients in 2050 20Million Patients to experience HF
  3. Heart Rate – Rythm control in normal renge
  4. ablation surgery
  5. Prevention of Strokes
  6. AF: Chronic, persistent
  7. Risk is transferred to the providers
  8. Genetic profiling for early detection
  9. Going upstream for the Genetics and the Prevention
Patrick Ellinor, MD, PhD
  • Director, Cardiac Arrhythmia Service, Massachusetts General Hospital
  • Associate Professor, Harvard Medical School
  1. AF in Men with Prostate Cancer and Women with Breast Cancer
  2. Pathological issues
  3. Cardiovergent or not
  4. poor definition of the AF underpinning
  5. NEW type of anticoagulation Safer that Warfrin
  6. 2/3 of AF are not on anticoagulation: Patient preference, doctor preference related to intolerance
  7. Screening AF with Genetics
Colleen Fowler
  • VP, GM, AF Solutions, Medtronic
  1. AF 26Billion spend in the Hospitals
  2. Outcome improvement
  3. Lowering AF burden is very beneficial – endpoint of freedom of 30 seconds of AF for patient with comorbidities
  4. AF – multiple CV diseases
  5. Identify AF earlier – US not labeled product for AF Patient, outcome data needed
  6. drug management – which patient will benefit: help only patients that will benefit not any patient
  7. Wholistic view of AF
Parashar Patel
  • VP, Global Health Policy, Boston Scientific
  1. Payment reduction,
  2. Chronic condition with Acute episodes, post procedure
  3. life style modification
  4. Benefits last 3 years, then they come back
  5. Payers and MDs will ask for changes in life style for chance of success [weight reduction reached to qualify for knee replacement]
  6. Frint end and backend improvement – room to be optimistic
Michael Rousseau
  • President, Cardiovascular and Neuromodulation, Abbott
  1. AF – inprovement of Patient quality of life
  2. extended patient life
  3. Innovation solutions : Improve Clinical outcomens and cost care reduction final Goal: CURE
  4. Each patient need the entire Tool Box creation of multiple tools
  5. Devices – how is the value determined? value delivered along a time span not insinq with cost
  6. Innovation in patient active participation in health management – tracking by Step,
  7. Incremental innovations
Steven Zelenkofske, DO
  • VP US Medical Affairs, CVMD TA, AstraZeneca
  1. Drugs for AF, biology of the disease little advancement, durg approach – understand the biology of the disease and streamline approach
  2. Disease progresses, remission,
  3. Is there a Biomarker as predictor for development of AF? delay onset of AF
  4. HTN is a potential cause of AF not in all cases
  5. Sleep Apnea, life style predictors of AF
  6. Drugs do not work have high toxicity for Arrhythmia 50% reduction in AF 25% placibo reduction – wrong target – Channels is not the right target
  7. Genomics and Biology — need to understand the disease better
3:35 pm – 4:05 pm
Boston Scientific Ballroom
1:1 Fireside Chat: Omar Ishrak, PhD, CEO, Medtronic
Moderator: Paul LaViolette
  • Managing Partner & COO, SV Life Sciences Advisers
  1. Technology and Value
  2. M&A
  3. Disease pathway
Omar Ishrak, PhD
  • CEO, Medtronic
  1. Innovations are the essence of Medical Devices development as mission in technology
  2. Training Challenge in Surgical Robotic – patient comfort of minimal invasive therapy, cost lower
  3. Antibacterial sleeve saves cost of hospitalization, id infection occur Medtronic reimburses Hospital
  4. Respect of NOT INVENTED HERE – internal and external
  5. M&A 0 TAVR internal development THEN acquisition, HTN – acquisition did not work
  6. DIABETIC PUMP  – investment in R&D over 15 years
  7. Care management as Services – therapy and care management
  8. Technology company paid when it is delivered: understand cohorts,
  9. Strategy: Chronic Disease: AF, ablation is needed –
  10. Strategy: episodic care – success of intervention and the recovery from acuity, HF compensation in early stageCRT – hospitalization one year after the intervention is not acceptable
  11. 9 and 10 are measuring outcome differently
  12. Mitral Valve – platform for new generation of diagnostics
  13. ETERNAL: recover fast, improve outcome
4:05 pm – 4:55 pm
Boston Scientific Ballroom
Heart Failure’s Therapeutic Mandate

One million patients are hospitalized annually for HF—80% of total US cost of HF management. After discharge from HF hospitalization, 24% are rehospitalized within 30 days, greater than 50% within 6 months. Perspective on disease management, addressing the issues of hospital readmission and optimizing therapies.

 

Moderator: Akshay Desai, MD
  • Director, Heart Failure Disease Management, Brigham and Women’s Hospital
  • Associate Professor, Harvard Medical School
  1. How to leverage Big data
  2. Need for new therapies – collaboration of Academia and Pharma and Hospital
Philip Adamson, MD
  • VP and Medical Director, Abbott
  1. HF – number of patient will double as Population grows and ages
  2. Pharmacogenetics will explain the pathophysiology
  3. Longterm management by specialist is important vs by PCP
  4. How do we randomize trials
  5. REIMBURSEMENT is key
  6. Glory of being persistant
Craig Basson, MD, PhD
  • VP, Global Translational Medicine Head (CVM), Novartis Institutes for BioMedical Research
  • Senior Lecturer, Harvard Medical School
  1. HF – lags behind
  2. heterogenous disease
  3. Preserve EF
  4. Genomics data collected on large population
  5. Big data is here, genotype, phynotypes,  – high quality data sets translation od data to therapeutics is coming
  6. Biomarkers important for endpoints
  7. Impresco – HF Drug with 20% improvement in EF
Marc Semigran, MD
  • CMO, Myokardia
  1. HF – genetic and cellular level needed – in Oncology this is basic
  2. Precision medicine requires, devices to download CMR Cardiovascular magnetic resonance imaging (CMR), – data on fibrotics
  3. diagnosis etiology of HF is complex
  4. Preclinical trials are very important for early insights
  5. Younger patient with cardiomiopaty and older patient
Kenneth Stein, MD
  • SVP, CMO, Global Health Policy, Rhythm Management, Boston Scientific
  1. CHF is s clinical Syndrome,
  2. Telemeter physiologic information
  3. Physiology of HF – is well understood vs AF
  4. Translation of pathophysiology to therapeutics NOT YET accomplished
  5. Impending HF – device better that BP by MS
  6. Combination of therapies – what strategies yield best outcome, 20,000 participants in Clinical Trials is the wrong practice
  7. Translational science fails when clinical trials fail
  8. Need to be in the long haul, there is a model to be successful
4:55 pm – 6:00 pm
Boston Scientific Ballroom
CLINICAL HIGHLIGHT: A New Chapter of PAD

PAD is the most challenging atherosclerotic syndrome, largely due to the technological challenges of managing peripheral artery disease through minimally invasive strategies. Top physician, governmental, and industry leaders in the field discuss the potential for new breakthroughs including novel implantable devices, pharmacologic approaches, and reductions in associated cardiovascular morbidity and mortality.

The panel will also discuss, Below The Knee: The Persisting Unmet Need

 

Moderator: Michael Jaff, DO
  • President, Newton-Wellesley Hospital, Partners Healthcare
  • Professor of Medicine, Harvard Medical School
  1. Reimbursement strategy for PAD
  2. Congratulate CMS for covering PAD
  3. Clinical Trial design for devices for PAD – limitations as to what to propose to FDA and CMS
Douglas Drachman, MD
  • Director, Cardiology and Interventional Cardiology Fellowship Programs, Massachusetts General Hospital
  • Assistant Professor of Medicine, Harvard Medical School
  1. Nine million patient PAD
  2. systemic therapy, early access to care, arterial insufficiancy, better vascularization
  3. Modification diet for atherosclerotic disease – Mediterranean diet – conselling patients on a regular basis
  4. training operator – baloons is a game changer
  5. durable patency – no need to go back
  6. systemic burden od atherosclerosis
  7. Public recognition of PAD as an important complex disease
Tamara Syrek Jensen
  • Director, Coverage and Analysis Group, CMS
  1. coverage incentives in the payment system
  2. design trials with FDA and CMS to ensure approval and reimbursement – know early
  3. Evidence-based tool, quality measure group
  4. CMS approach for site of treatment/service so to be reimbursed
  5. “Reasonable and Necessary” definition for PAD treatment – CMS continue to be innovative
  6. CMS needs data to cover technology
  7. CMS wishes to work with MDs
Misti Malone, PhD
  • Chief, Peripheral Interventional Devices Branch, Food and Drug Administration
  1. heterogeneity, lack of data
  2. devices approval require consistent data, collaboration with NIH, CMS – design meaningful trials
  3. Match patients and match treatment
  4. mulriple companies work with FDA – FDA is willing to accept treatment, benefit and the labeling claims
  5. Early contacting FDA
Shaden Marzouk, MD
  • CMO, Cardinal Health
  1. neuronal claudication vs vascular claudication
  2. continnum of care
Matthew Menard, MD
  • Co-Director, Endovascular Surgery, Brigham and Women’s Hospital
  • Assistant Professor, Harvard Medical School
  • Critical Limb Ischemia (CLI)
  • 3D Printing – morphologic information on density and on patency
  • PAD is a tremendous challlenge PCI was solved PAD not yet
Jeff Mirviss
  • SVP and President, Peripheral Interventions, Boston Scientific
  1. ANTI peripheral therapies – above the knee and below the knee – different vessels
  2. No Consistency in wound care across institutions  – complexity on top of complexity
  3. Balance of rigorous science with adjustment by FDA
  4. Strategy – Category Leadership: not a singular technology: Bare stent, Stant and baloon and drug eluting stent
  5. PAD atherectomy
  6. Stem cells harvesting for clinical Trial – early stage research to assist patient early rather at late stage
  7. PAD Options is evolving
6:00 pm – 6:45 pm
Lilly Foyer
Opening Reception

Posted in Cardiac and Cardiovascular Surgical Procedures, Conference Coverage with Social Media, Frontiers in Cardiology and Cardiovascular Disorders, Scientific & Biotech Conferences: Press Coverage | Leave a Comment »

Doudna and Charpentier and their teams to receive wide-ranging patents in many countries: European Patent Office (EPO) and UK Intellectual Property Office – broad patent for CRISPR-Cas9 gene-editing technology to the University of California and the University of Vienna

April 28, 2017 by 2012pharmaceutical

Doudna and Charpentier and their teams to receive wide-ranging patents in many countries:  European Patent Office (EPO) and UK Intellectual Property Office – broad patent for CRISPR-Cas9 gene-editing technology to the University of California and the University of Vienna, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

Doudna and Charpentierand their teams to receive wide-ranging patents in many countries:  European Patent Office (EPO) and UK Intellectual Property Office – broad patent for CRISPR-Cas9 gene-editing technology to the University of California and the University of Vienna

Reporter: Aviva Lev-Ari, PhD, RN

 

The EPO patent will cover the single-guide CRISPR-Cas9 technology in cells of all types. The technology was invented by Jennifer Doudna, a UC Berkeley professor of molecular and cell biology, Charpentier, now director of the Max Planck Institute for Infection Biology in Berlin, and their colleagues. Applications include treatment of various human diseases, as well as veterinary, agricultural and other biotech applications. The European patent would cover some 40 countries, including France, Germany, Italy, Spain, the Netherlands and Switzerland.

The EPO has stated its intent to grant a patent with claims that encompass all cells, despite objections from third parties, including the Broad Institute, a joint research institute of Harvard University and the Massachusetts Institute of Technology.

“We are excited that this patent will issue based on the foundational research we published with Emmanuelle Charpentier and the rest of our team. We look forward to the continued applications of gene-editing technology to solve problems in human health and agriculture,” said Doudna, who is a Howard Hughes Medical investigator at UC Berkeley.

The UC patent application to the EPO was substantially the same as the UC patent application filed in the United States. In the U.S., UC claims covering the use of single-guide CRISPR-Cas9 technology in any setting were found to be allowable by the U.S. Patent & Trademark Office, and were placed in an interference with patents owned by the Broad Institute that cover use of the technology in eukaryotic cells. An interference is a formal legal proceeding before the Patent Trial and Appeal Board (PTAB) to determine who was the first to invent.

“We disagree with the recent PTAB decision to terminate the interference between claims of the UC and the Broad Institute, and we are keeping all of our options open, including the possibility of an appeal,” Penhoet said. “We remain confident that when the inventorship question is finally answered, the Doudna and Charpentier teams will prevail.”

WATCH VIDEO

SOURCE

http://news.berkeley.edu/2017/03/28/european-patent-office-to-grant-uc-a-broad-patent-on-crispr-cas9/

Other related articles published in this Open Access Online Scientific Journal include the following:

Gene Editing Consortium of Biotech Companies: CRISPR Therapeutics $CRSP, Intellia Therapeutics $NTLA, Caribou Biosciences, ERS Genomics, UC, Berkeley (Doudna’s IP) and University of Vienna (Charpentier’s IP), is appealing the decision ruled that there was no interference between the two sides, to the U.S. Court of Appeals for the Federal Circuit, targeting patents from The Broad Institute.

https://pharmaceuticalintelligence.com/2017/04/13/gene-editing-consortium-of-biotech-companies-crispr-therapeutics-crsp-intellia-therapeutics-ntla-caribou-biosciences-and-ers-genomics-uc-berkeley-doudnas-ip-and-university-of-vienna-charpe/

 

Keyword Search: CRISPR – 247 articles in pharmaceuticalintelligence.com

https://pharmaceuticalintelligence.com/?s=CRISPR

 

Posted in CRISPR/Cas9 & Gene Editing | Leave a Comment »

Sleep Research Society announces 2017 award recipients including Thomas S. Kilduff, PhD, Director, Center for Neuroscience at SRI International in Menlo Park, California

April 28, 2017 by 2012pharmaceutical

2017 award recipients including Thomas S. Kilduff, PhD, Director, Center for Neuroscience at SRI International in Menlo Park, California

 

Reporter: Aviva Lev-Ari, PhD, RN

I was Director of the Business and Economic Statistics Program at SRI International in Menlo Park, California, 1985-1988.

Sleep Research Society announces 2017 award recipients

Sleep Research Society
Friday, April 28, 2017

DARIEN, IL – Several of the world’s leading sleep and circadian scientists were selected as recipients of the 2017 Sleep Research Society awards, which will be presented Monday, June 5, during the plenary session of SLEEP 2017, the 31st annual meeting of the Associated Professional Sleep Societies LLC (APSS) in Boston.

“The Sleep Research Society awards recognize individuals who have made significant and lasting contributions to sleep and circadian science,” said SRS President Sean P.A. Drummond, PhD. “I congratulate each of the recipients of the 2017 awards and appreciate all that they have done to help the SRS achieve its mission to advance sleep and circadian science.”

The 2017 SRS award recipients, who were selected by the SRS board of directors, are:

Thomas S. Kilduff, PhD
Distinguished Scientist Award for significant, original and sustained scientific contributions of a basic, clinical or theoretical nature to the sleep and circadian research field, made over an entire career
Dr. Kilduff directs the Center for Neuroscience at SRI International in Menlo Park, California. He is co-discoverer of the neuropeptide hypocretin (orexin), a key neurotransmitter in the maintenance of wakefulness. His group at SRI has identified a cortical interneuron population that is activated during sleep in proportion to homeostatic sleep drive, and their work also focuses on therapeutic development for insomnia and narcolepsy.

As the SRS Distinguished Scientist Award recipient, Dr. Kilduff also receives the honor of presenting an invited lecture at the SLEEP 2017 annual meeting. He will present the lecture, “Identifying Novel Sleep/Wake Targets: Hypocretin/Orexin, Cortical nNOS Neurons, and TAAR1,” on Tuesday, June 6, at the Hynes Convention Center in Boston.

Niels C. Rattenborg, PhD
Outstanding Scientific Achievement Award for novel and seminal discoveries of a basic, clinical or theoretical nature that have made a significant impact on the sleep field
Dr. Rattenborg is the leader of the Avian Sleep Group at the Max Planck Institute for Ornithology (MPIO) in Seewiesen, Germany. His research, published in August 2016 in the journal Nature Communications, was the first to demonstrate sleep in flying birds. Using electroencephalogram recordings of great frigatebirds flying over the ocean for up to 10 days, his team found that the birds can sleep with either one hemisphere at a time or both hemispheres simultaneously. However, while in flight they sleep for a much smaller percentage of time than they do while on land, which challenges the dominant view that large daily amounts of sleep are required to maintain adaptive performance.

Colin A. Espie, PhD, DSc
Mary A. Carskadon Outstanding Educator Award for excellence in the field of education related to sleep medicine and sleep research
Dr. Espie is professor of sleep medicine in the Nuffield Department of Clinical Neuroscience and a Fellow of Somerville College at the University of Oxford in England. He is research director of the Experimental and Clinical Sleep Medicine program within the Sleep & Circadian Neuroscience Institute and clinical director of the Oxford Online Program in Sleep Medicine.

Photos are available upon request. For more information, please contact Specialty Society Coordinator Barbara Hoeft at 630-737-9700, ext. 9321, or bhoeft@srsnet.org.

About the Sleep Research Society
The Sleep Research Society (SRS) is a professional membership society that advances sleep and circadian science. The SRS provides forums for the exchange of information, establishes and maintains standards of reporting and classifies data in the field of sleep research, and collaborates with other organizations to foster scientific investigation on sleep and its disorders. The SRS also publishes the peer-reviewed, scientific journal SLEEP.

SOURCE

http://www.sleepresearchsociety.org/articles.aspx?id=6867

Posted in Innovations in Neurophysiology & Neuropsychology | Tagged | Leave a Comment »

Updated on 4/14/2019 –>> FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018

April 28, 2017 by 2012pharmaceutical

Updated on 4/14/2019 –>>

FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com,

Top Articles by Author and by e-Views >1,000,

4/27/2012 to 1/29/2018

UPDATED on 4/14/2019

Top Posts for all days ending 2019-04-14 (Summarized)

All Time

Title Views
Home page / Archives More stats 615,383
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? More stats 16,839
Do Novel Anticoagulants Affect the PT/INR? The Cases of

XARELTO (rivaroxaban) and PRADAXA (dabigatran)

 More stats 13,438
Paclitaxel vs Abraxane (albumin-bound paclitaxel) More stats 12,530
Recent comprehensive review on the role of

ultrasound in breast cancer management

 More stats 12,188
Clinical Indications for Use of Inhaled Nitric Oxide (iNO)

in the Adult Patient Market: Clinical Outcomes after Use,

Therapy Demand and Cost of Care

 More stats 7,318
Apixaban (Eliquis): Mechanism of Action, Drug

Comparison and Additional Indications

 More stats 6,927
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) More stats 6,361
Our TEAM More stats 6,258
Biochemistry of the Coagulation Cascade and

Platelet Aggregation: Nitric Oxide: Platelets, Circulatory

Disorders, and Coagulation Effects

 More stats 4,790
Akt inhibition for cancer treatment, where do we stand today? More stats 4,776
AstraZeneca’s WEE1 protein inhibitor AZD1775

Shows Success Against Tumors with a SETD2 mutation

 More stats 4,231
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses More stats 4,221
Interaction of enzymes and hormones More stats 3,849
The Centrality of Ca(2+) Signaling and Cytoskeleton

Involving Calmodulin Kinases and Ryanodine Receptors

in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic

Arrhythmia, Similarities and Differences, and Pharmaceutical Targets

 More stats 3,758
FDA Guidelines For Developmental and Reproductive

Toxicology (DART) Studies for Small Molecules

 More stats 3,737
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the

Hemeostasis of Immune Responses for Good and Bad

 More stats 3,706
Cardiovascular Diseases, Volume One: Perspectives on

Nitric Oxide in Disease Mechanisms

 More stats 3,580
Causes and imaging features of false positives and

false negatives on 18F-PET/CT in oncologic imaging

 More stats 3,543
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology More stats 3,434
Founder More stats 3,428
AMPK Is a Negative Regulator of the Warburg Effect and

Suppresses Tumor Growth In Vivo

 More stats 3,414
BioMed e-Series More stats 3,267
Signaling and Signaling Pathways More stats 3,233
Sexed Semen and Embryo Selection in Human

Reproduction and Fertility Treatment

 More stats 3,224
The History and Creators of Total Parenteral Nutrition More stats 3,175
Alternative Designs for the Human Artificial Heart:

Patients in Heart Failure – Outcomes of Transplant

(donor)/Implantation (artificial) and Monitoring Technologies

for the Transplant/Implant Patient in the Community

 More stats 3,109
2019 VISION More stats 3,069
Bone regeneration and nanotechnology More stats 3,025
The mechanism of action of the drug ‘Acthar’ for Systemic

Lupus Erythematosus (SLE)

 More stats 3,022
Targeting the Wnt Pathway [7.11] More stats 3,011
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and

Cardiac Resynchronization Therapy (CRT)

 More stats 2,954
Isoenzymes in cell metabolic pathways More stats 2,822
Paclitaxel: Pharmacokinetic (PK), Pharmacodynamic (PD) and

Pharmacogenpmics (PG)

 More stats 2,811
FDA Adds Cardiac Drugs to Watch List – TOPROL-XL® More stats 2,758
Funding, Deals & Partnerships More stats 2,738
LIK 066, Novartis, for the treatment of type 2 diabetes More stats 2,732
Nitric Oxide and Platelet Aggregation More stats 2,621
Mitochondria: Origin from oxygen free environment, role in

aerobic glycolysis, metabolic adaptation

 More stats 2,590
Nitric Oxide Function in Coagulation – Part II More stats 2,583
Treatment Options for Left Ventricular Failure – Temporary

Circulatory Support: Intra-aortic balloon pump (IABP) –

Impella Recover LD/LP 5.0 and 2.5, Pump Catheters

(Non-surgical) vs Bridge Therapy: Percutaneous Left

Ventricular Assist Devices (pLVADs) and LVADs (Surgical)

 More stats 2,577
Evolution of Myoglobin and Hemoglobin More stats 2,556
Pyrroloquinoline quinone (PQQ) – an unproved supplement More stats 2,551
Monoclonal Antibody Therapy and Market More stats 2,542
“The Molecular pathology of Breast Cancer Progression” More stats 2,493
In focus: Circulating Tumor Cells More stats 2,480
Update on FDA Policy Regarding 3D Bioprinted Material More stats 2,457
Integrins, Cadherins, Signaling and the Cytoskeleton More stats 2,401
A Primer on DNA and DNA Replication More stats 2,378
Journal PharmaceuticalIntelligence.com More stats 2,370
DNA Structure and Oligonucleotides More stats 2,210
Lipid Metabolism More stats 2,203
Swiss Paraplegic Centre, Nottwil, Switzerland – A World-

Class Clinic for Spinal Cord Injuries

 More stats 2,193
Non-small Cell Lung Cancer drugs – where does the Future lie? More stats 2,181
Sex Hormones More stats 2,164
Biosimilars: CMC Issues and Regulatory Requirements More stats 2,143
The SCID Pig: How Pigs are becoming a Great Alternate

Model for Cancer Research

 More stats 2,122
About More stats 2,079
CD47: Target Therapy for Cancer More stats 2,070
Peroxisome proliferator-activated receptor (PPAR-gamma)

Receptors Activation: PPARγ transrepression for

Angiogenesis in Cardiovascular Disease and PPARγ

transactivation for Treatment of Diabetes

 More stats 2,034
The History of Infectious Diseases and Epidemiology in the late 19th and 20th Century More stats 2,025
Introduction to Tissue Engineering; Nanotechnology applications More stats 1,987
Problems of vegetarianism More stats 1,943
Unique Selling Proposition (USP) — Building Pharmaceuticals Brands More stats 1,896
The top 15 best-selling cancer drugs in 2022 & Projected

Sales in 2020 of World’s Top Ten Oncology Drugs

 More stats 1,890
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node More stats 1,822
Wnt/β-catenin Signaling [7.10] More stats 1,814
The role of biomarkers in the diagnosis of sepsis and patient management More stats 1,773
Neonatal Pathophysiology More stats 1,768
Sex determination vs. Sex differentiation More stats 1,747
Scientific and Medical Affairs Chronological CV More stats 1,730
Ultrasound-based Screening for Ovarian Cancer More stats 1,726
Nanotechnology and MRI imaging More stats 1,684
Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert,

Author, Writer, Editor & Content Consultant for e-SERIES A:

Cardiovascular Diseases

 More stats 1,682
Cardiovascular Complications: Death from Reoperative

Sternotomy after prior CABG, MVR, AVR, or Radiation;

Complications of PCI; Sepsis from Cardiovascular Interventions

 More stats 1,668
Stenting for Proximal LAD Lesions More stats 1,649
Nitric Oxide, Platelets, Endothelium and Hemostasis

(Coagulation Part II)

 More stats 1,626
Competition in the Ecosystem of Medical Devices in

Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization

Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS)

 More stats 1,617
Mitral Valve Repair: Who is a Patient Candidate for a

Non-Ablative Fully Non-Invasive Procedure?

 More stats 1,616
Diet and Diabetes More stats 1,601
Outcomes in High Cardiovascular Risk Patients: Prasugrel

(Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB

 More stats 1,593
Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays More stats 1,583
Altitude Adaptation More stats 1,562
Clinical Trials Results for Endothelin System:

Pathophysiological role in Chronic Heart Failure, Acute

Coronary Syndromes and MI – Marker of Disease

Severity or Genetic Determination?

 More stats 1,557
Cytoskeleton and Cell Membrane Physiology More stats 1,549
Biosimilars: Intellectual Property Creation and

Protection by Pioneer and by Biosimilar Manufacturers

 More stats 1,536
Interview with the co-discoverer of the structure of DNA:

Watson on The Double Helix and his changing view of Rosalind Franklin

 More stats 1,520
Baby’s microbiome changing due to caesarean birth and formula feeding More stats 1,500
Triple Antihypertensive Combination Therapy

Significantly Lowers Blood Pressure in Hard-to-Treat

Patients with Hypertension and Diabetes

 More stats 1,500
Cancer Signaling Pathways and Tumor Progression:

Images of Biological Processes in the Voice of a Pathologist Cancer Expert

 More stats 1,499
CRISPR/Cas9: Contributions on Endoribonuclease

Structure and Function, Role in Immunity and Applications in Genome Engineering

 More stats 1,483
Signaling transduction tutorial More stats 1,477
IDO for Commitment of a Life Time: The Origins and

Mechanisms of IDO, indolamine 2, 3-dioxygenase

 More stats 1,475
Diagnostic Evaluation of SIRS by Immature Granulocytes More stats 1,454
A New Standard in Health Care – Farrer Park Hospital,

Singapore’s First Fully Integrated Healthcare/Hospitality Complex

 More stats 1,454
Nitric Oxide and it’s impact on Cardiothoracic Surgery More stats 1,449
Nanotechnology and Heart Disease More stats 1,443
Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects More stats 1,443
Aviva Lev-Ari, PhD, RN, Director and Founder More stats 1,439
Cardio-oncology and Onco-Cardiology Programs:

Treatments for Cancer Patients with a History of Cardiovascular Disease

 More stats 1,432
UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better

than Plavix® (clopidogrel bisulfate): Lowering chances of

having another heart attack

 More stats 1,430
Ovarian Cancer and fluorescence-guided surgery: A report More stats 1,427
LPBI Group More stats 1,411
Mitochondrial Damage and Repair under Oxidative Stress More stats 1,406
Medical 3D Printing More stats 1,374
Closing the Mammography gap More stats 1,368
Crucial role of Nitric Oxide in Cancer More stats 1,366
Disruption of Calcium Homeostasis: Cardiomyocytes and

Vascular Smooth Muscle Cells: The Cardiac and

Cardiovascular Calcium Signaling Mechanism

 More stats 1,331
Survivals Comparison of Coronary Artery Bypass Graft (CABG)

and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty

 More stats 1,330
Summary of Lipid Metabolism More stats 1,330
The Final Considerations of the Role of Platelets and Platelet

Endothelial Reactions in Atherosclerosis and Novel Treatments

 More stats 1,324
Inactivation of the human papillomavirus E6 or E7 gene in

cervical carcinoma cells using a bacterial CRISPR/Cas

 More stats 1,321
Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors More stats 1,294
Mitochondrial Dynamics and Cardiovascular Diseases More stats 1,290
Nitric Oxide and Immune Responses: Part 2 More stats 1,290
Autophagy More stats 1,264
Mitochondrial fission and fusion: potential therapeutic targets? More stats 1,250
Nitric Oxide has a Ubiquitous Role in the Regulation of

Glycolysis – with a Concomitant Influence on Mitochondrial Function

 More stats 1,250
Gamma Linolenic Acid (GLA) as a Therapeutic tool in the

Management of Glioblastoma

 More stats 1,245
Linus Pauling: On Lipoprotein(a) Patents and On Vitamin C More stats 1,239
Development Of Super-Resolved Fluorescence Microscopy More stats 1,217
Future of Calcitonin…? More stats 1,211
Transcatheter Aortic Valve Implantation (TAVI): FDA approves

expanded indication for two transcatheter heart valves for

patients at intermediate risk for death or complications

associated with open-heart surgery

 More stats 1,198
Ubiquitin-Proteosome pathway, Autophagy, the Mitochondrion,

Proteolysis and Cell Apoptosis: Part III

 More stats 1,188
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly More stats 1,186
Bystolic’s generic Nebivolol – Positive Effect on circulating

Endothelial Progenitor Cells Endogenous Augmentation

 More stats 1,185
A Patient’s Perspective: On Open Heart Surgery from

Diagnosis and Intervention to Recovery

 More stats 1,183
Nanotechnology and HIV/AIDS Treatment More stats 1,183
Patiromer – New drug for Hyperkalemia More stats 1,182
The History of Hematology and Related Sciences More stats 1,179
Heroes in Medical Research: Barnett Rosenberg and

the Discovery of Cisplatin

 More stats 1,178
Atrial Fibrillation contributing factor to Death, Autopsy

suggests CEO Dave Goldberg had heart arrhythmia before death

 More stats 1,176
Assessing Cardiovascular Disease with Biomarkers More stats 1,168
Imatinib (Gleevec) May Help Treat Aggressive Lymphoma:

Chronic Lymphocytic Leukemia (CLL)

 More stats 1,163
Overview of New Strategy for Treatment of T2DM:

SGLT2 Inhibiting Oral Antidiabetic Agents

 More stats 1,154
Issues in Personalized Medicine in Cancer:

Intratumor Heterogeneity and Branched Evolution

Revealed by Multiregion Sequencing

 More stats 1,137
Amyloidosis with Cardiomyopathy More stats 1,133
New England Compounding Center: A Family Business More stats 1,128
Carbohydrate Metabolism More stats 1,126
EpCAM [7.4] More stats 1,125
Acoustic Neuroma, Neurinoma or Vestibular

Schwannoma: Treatment Options

 More stats 1,118
Proteomics – The Pathway to Understanding and Decision-making in Medicine More stats 1,113
Can Mobile Health Apps Improve Oral-Chemotherapy

Adherence? The Benefit of Gamification.

 More stats 1,096
A NEW ERA OF GENETIC MANIPULATION   More stats 1,095
Treatment of Refractory Hypertension via Percutaneous Renal Denervation More stats 1,090
Pancreatic Cancer: Genetics, Genomics and Immunotherapy More stats 1,087
Low Bioavailability of Nitric Oxide due to Misbalance in

Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model

 More stats 1,086
Pharma World: The Pharmaceutical Industry in Southeast Asia –

Pharma CPhI 20-22 March, 2013, Jakarta International

Expo, Jakarta, Indonesia

 More stats 1,083
Targeting Mitochondrial-bound Hexokinase for Cancer Therapy More stats 1,079
Normal and Anomalous Coronary Arteries:

Dual Source CT in Cardiothoracic Imaging

 More stats 1,071
Transdermal drug delivery (TDD) system and nanotechnology: Part II More stats 1,071
Lung Cancer (NSCLC), drug administration and nanotechnology More stats 1,067
Nitric Oxide and Sepsis, Hemodynamic Collapse, and

the Search for Therapeutic Options

 More stats 1,063
Highlights in the History of Physiology More stats 1,059
Press Coverage More stats 1,058
Top Ten Cardiovascular Medical Devices Companies –

the Share of Top Institutional Investors

 More stats 1,056
Targeted delivery of therapeutics to bone and connective tissues:

current status and challenges- Part I

 More stats 1,052
Open Abdominal Aortic Aneurysm (AAA) repair (OAR) vs.

Endovascular AAA Repair (EVAR) in Chronic Kidney

Disease Patients – Comparison of Surgery Outcomes

 More stats 1,041
Acute Lymphoblastic Leukemia (ALL) and Nanotechnology More stats 1,034
Summary of Transcription, Translation ond Transcription Factors More stats 1,025
In focus: Melanoma Genetics More stats 1,019
Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of

Anacetrapib to treat Atherosclerosis and CAD

 More stats 1,015
Medical Devices Start Ups in Israel: Venture Capital

Sourced Locally – Rainbow Medical (GlenRock) & AccelMed (Arkin Holdings)

 More stats 1,011
Summary, Metabolic Pathways More stats 1,009
Protein Energy Malnutrition and Early Child Development More stats 1,009
No Early Symptoms – An Aortic Aneurysm Before It Ruptures –

Is There A Way To Know If I Have it?

 More stats 1,005
The Development of siRNA-Based Therapies for Cancer More stats 1,005
Soft Tissue Sarcoma: an Overview More stats 1,005
Sepsis, Multi-organ Dysfunction Syndrome, and Septic Shock:

A Conundrum of Signaling Pathways Cascading Out of Control

 More stats 1,000

 

 

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

 

FIVE years of e-Scientific Publishing  –  Top Articles by e-Views >1,000 for all days ending 2018-01-29 (Summarized)

@pharmaceuticalintellicence.com
 
Article Title

e-Readers

Views

All Time

1/29/2018

 

e-Readers

Views

All Time

4/27/2017

 Author’s Name

 

Home page / Archives

 521,463

 445,321

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?  16,114 15,461 Larry H. Bernstein, MD, FCAP
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)  11,606 10,005  

Vivek Lal, MBBS, MD, FCIR, Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Recent comprehensive review on the role of ultrasound in breast cancer management  9,182 7,513 Dror Nir, PhD
Paclitaxel vs Abraxane (albumin-bound paclitaxel)  8,781 6,721 Tilda Barliya, PhD
Our TEAM  5,934 5,722 Aviva Lev-Ari, PhD, RN
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)  5,911 5,380 Tilda Barliya, PhD
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care  5,865 4,379 Aviva Lev-Ari, PhD, RN
Akt inhibition for cancer treatment, where do we stand today?  4,333 4,077 Ziv Raviv, PhD
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses  3.962 3,847 Zohi Sternberg, PhD
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications  4,551 3,609 Aviva Lev-Ari, PhD, RN
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms  3,521 3,456 Larry H. Bernstein, MD, FCAP, Stephen J Williams, PhD, Aviral Vatsa, PhD, et al.
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad  3,558 3,330 Demet Sag, PhD
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo  3,305 3,215 Stephen J Williams, PhD
Founder  3,257 3,131 Aviva Lev-Ari, PhD, RN
BioMed e-Series  3,140 3,005 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN,

et al.
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology  3,064 2,866 Tilda Barliya, PhD
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets  3,138 2,854 Larry H. Bernstein, MD, FCAP, Justin D. Pearlman, MD, PhD and Aviva Lev-Ari, PhD, RN
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I  3,673 2,677 Larry H. Bernstein, MD, FCAP
VISION  2,803 2,651 Aviva Lev-Ari, PhD, RN
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community  2,776 2,602 Justin D. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Funding, Deals & Partnerships  2,601 2,506 Aviva Lev-Ari, PhD, RN
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules  2,946 2,461 Stephen J Williams, PhD
Bone regeneration and nanotechnology  2,643 2,446 Tilda Barliya, PhD
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging  2,854 2,400 Dror Nir, PhD
“The Molecular pathology of Breast Cancer Progression”  2,436 2,315 Tilda Barliya, PhD
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation  2,514 2,240 Larry H. Bernstein, MD, FCAP
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT)  2,544 2,190 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Targeting the Wnt Pathway [7.11]  2,611 2,162 Larry H. Bernstein, MD, FCAP
In focus: Circulating Tumor Cells  2,247 2,151 Ritu Saxena, PhD
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical)  2,321 2,110 Justin D. Pearlman, MD, PhD, FACC

and

Larry H. Bernstein, MD, FCAP
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation  3,458 2,100 Stephen J Williams, PhD
Journal PharmaceuticalIntelligence.com  2,214 2,068 Aviva Lev-Ari, PhD, RN and  et al.
About  2,054 2,044 Aviva Lev-Ari, PhD, RN
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment  2,456 2,028 Sudipta Saha, PhD
Interaction of enzymes and hormones  2,654 1,994 Larry H. Bernstein, MD, FCAP
Problems of vegetarianism
1,925  1,908 Sudipta Saha, PhD
DNA Structure and Oligonucleotides  2,016 1,905 Larry H. Bernstein, MD, FCAP
Biosimilars: CMC Issues and Regulatory Requirements  1,953 1,813 Aviva Lev-Ari, PhD, RN
CD47: Target Therapy for Cancer  1,907 1,763 Tilda Barliya, PhD
Lipid Metabolism  1,968 1,761 Larry H. Bernstein, MD, FCAP
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes  1,919 1,761 Aviva Lev-Ari, PhD, RN
Paclitaxel: Pharmacokinetic (PK), Pharmacodynamic (PD) and Pharmacogenpmics (PG)  2,189 1,725 Tilda Barliya, PhD
Non-small Cell Lung Cancer drugs – where does the Future lie?  1,867 1,720 Ritu Saxena, PhD
A Primer on DNA and DNA Replication  2,001 1,720 Larry H. Bernstein, MD, FCAP
Introduction to Tissue Engineering; Nanotechnology applications  1,998 1,711 Tilda Barliya, PhD
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node 1,767 1,667 Tilda Barliya, PhD
Nitric Oxide Function in Coagulation – Part II  1,965 1,614 Larry H. Bernstein, MD, FCAP
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research  1,795 1,603 Stephen J Williams, PhD
FDA Adds Cardiac Drugs to Watch List – TOPROL-XL®  2,059 1,578 Aviva Lev-Ari, PhD, RN
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB 1,561 1,542 Aviva Lev-Ari, PhD, RN
The role of biomarkers in the diagnosis of sepsis and patient management  1,659 1,500 Larry H. Bernstein, MD, FCAP
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers  1,513 1,475 Aviva Lev-Ari, PhD, RN
Nanotechnology and MRI imaging  1,574 1,470 Tilda Barliya, PhD
Baby’s microbiome changing due to caesarean birth and formula feeding  1,492 1,457 Aviva Lev-Ari, PhD, RN
Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions  1,598 1,453 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays  1,472 1,424 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?  1,472 1,417 Aviva Lev-Ari, PhD, RN
Neonatal Pathophysiology 1,562 1,412 Larry H. Bernstein, MD, FCAP
Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) 1,518 1,408 Aviva Lev-Ari, PhD, RN
Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases  1,527 1,396 Justin D. Pearlman, MD, PhD, FACC
IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase 1,423 1,384 Demet Sag, PhD
UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better than Plavix® (clopidogrel bisulfate): Lowering chances of having another heart attack  1,407 1,360 Aviva Lev-Ari, PhD, RN
Monoclonal Antibody Therapy and Market  1,854 1,352 Demet Sag, PhD
Mitochondrial Damage and Repair under Oxidative Stress  1,355 1,315 Larry H. Bernstein, MD, FCAP
Closing the Mammography gap  1,325 1,292 Dror Nir, PhD
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease  1,374 1,288 Aviva Lev-Ari, PhD, RN
Update on FDA Policy Regarding 3D Bioprinted Material  2,011 1,286 Aviva Lev-Ari, PhD, RN
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure?  1,493 1,276 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN, Director and Founder  1,317 1,250 Aviva Lev-Ari, PhD, RN
Diagnostic Evaluation of SIRS by Immature Granulocytes  1,328 1,249 Larry H. Bernstein, MD, FCAP
Nitric Oxide, Platelets, Endothelium and Hemostasis (Coagulation Part II) 1,400 1,238 Larry H. Bernstein, MD, FCAP
Signaling and Signaling Pathways  2,598 1,235 Larry H. Bernstein, MD, FCAP
Crucial role of Nitric Oxide in Cancer  1,309 1,215 Ritu Saxena, PhD
Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes  1,339 1,211 Aviva Lev-Ari, PhD, RN
Mitochondrial fission and fusion: potential therapeutic targets?  1,230 1,203 Ritu Saxena, PhD
Diet and Diabetes  1,370 1,186 Larry H. Bernstein, MD, FCAP
Mitochondrial Dynamics and Cardiovascular Diseases  1,225 1,171 Ritu Saxena, PhD
Nanotechnology and Heart Disease  1,300 1,159 Tilda Barliya, PhD
Nitric Oxide and Immune Responses: Part 2  1,186 1,153 Aviral Vatsa, PhD
Transcatheter Aortic Valve Implantation (TAVI): FDA approves expanded indication for two transcatheter heart valves for patients at intermediate risk for death or complications associated with open-heart surgery  1,182 1,153 Aviva Lev-Ari, PhD, RN
The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis and Novel Treatments  1,217 1,149 Larry H. Bernstein, MD, FCAP
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly  1,151 1,128 Aviva Lev-Ari, PhD, RN
Scientific and Medical Affairs Chronological CV  1,336 1,127 Aviva Lev-Ari, PhD, RN
Assessing Cardiovascular Disease with Biomarkers  1,146 1,122 Larry H. Bernstein, MD, FCAP
Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing 1,127 1,116 Stephen J Williams, PhD
Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors  1,167 1,112 Stephen J Williams, PhD
Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis – with a Concomitant Influence on Mitochondrial Function  1,146 1,111 Larry H. Bernstein, MD, FCAP
Nanotechnology and HIV/AIDS treatment  1,160 1,109 Tilda Barliya, PhD
Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin 1,230 1,107 Aviva Lev-Ari, PhD, RN
Ultrasound-based Screening for Ovarian Cancer  1,269 1,105 Dror Nir, PhD
Stenting for Proximal LAD Lesions  1,345 1,082 Aviva Lev-Ari, PhD, RN
Treatment of Refractory Hypertension via Percutaneous Renal Denervation  1,085 1,082 Aviva Lev-Ari, PhD, RN
Nitric Oxide and it’s impact on Cardiothoracic Surgery  1,268 1,079 Tilda Barliya, PhD
Wnt/β-catenin Signaling [7.10]  1,480 1,078 Larry H. Bernstein, MD, FCAP
Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism 1,174 1,068 Larry H. Bernstein, MD, FCAP,             Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Unique Selling Proposition (USP) — Building Pharmaceuticals Brands  1,342 1,063 Aviva Lev-Ari, PhD, RN
Patiromer – New drug for Hyperkalemia  1,113 1,054 Aviva Lev-Ari, PhD, RN
Isoenzymes in cell metabolic pathways  1,462 1,048 Larry H. Bernstein, MD, FCAP
Sex Hormones  1,391 1,039 Larry H. Bernstein, MD, FCAP
LPBI Group  1,201 1,027 Aviva Lev-Ari, PhD, RN
Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty 1,227 1,027 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Targeted delivery of therapeutics to bone and connective tissues: current status and challenges- Part I  1,031 1,020 Aviral Vatsa, PhD
Overview of New Strategy for Treatment of T2DM: SGLT2 Inhibiting Oral Antidiabetic Agents  1,049 1,015 Aviral Vatsa, PhD
Ovarian Cancer and fluorescence-guided surgery: A report  1,167 1,012 Tilda Barliya, PhD
Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation  1,059 1,012 Aviva Lev-Ari, PhD, RN
Low Bioavailability of Nitric Oxide due to Misbalance in Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model  1,045 1,011 Anamika Sarkar, PhD
New England Compounding Center: A Family Business  1,064 1,008 Alan F. Kaul, PharmD
Integrins, Cadherins, Signaling and the Cytoskeleton  1,498 1,003 Larry H. Bernstein, MD, FCAP

Posted in LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management | Leave a Comment »

Tax Cuts Potential Impact on Overseas (ex-US accounts) by Top 9 Biopharma holdings of $133B in M&A

April 27, 2017 by 2012pharmaceutical

Tax Cuts Potential Impact on Overseas (ex-US accounts) by Top 9 Biopharma holdings of $133B in M&A 

Reporter: Aviva Lev-Ari, PhD, RN

 

Amgen has been sheltering a cache of about $35 billion in ex-US accounts, according to some numbers that EvercoreISI’s Umer Raffat put together as he began assessing the impact tax reform could have on the top players in overseas holdings.

 

SOURCE

The top 9 overseas accounts in biopharma hold $133B in M&A firepower by john carroll April 27, 2017 06:42 AM EDT, Updated: 08:15 AM

https://endpts.com/the-top-9-overseas-accounts-in-biopharma-hold-133b-in-ma-firepower/?utm_medium=email&utm_campaign=210%20Thursday%2042717%20Roche%20quietly%20dumps%20a%2017B%20drug%20Biotech%20upstart%20hatches%20a%20fresh%20approach%20to%20RD&utm_content=210%20Thursday%2042717%20Roche%20quietly%20dumps%20a%2017B%20drug%20Biotech%20upstart%20hatches%20a%20fresh%20approach%20to%20RD+CID_9462853ec6cf52ba4c323808bce33705&utm_source=ENDPOINTS%20emails&utm_term=The%20top%209%20overseas%20accounts%20in%20biopharma%20hold%20133B%20in%20MA%20firepower

Posted in Pharmaceutical Industry Competitive Intelligence | Leave a Comment »

Pharmacotyping Pancreatic Cancer Patients in the Future: Two Approaches – ORGANOIDS by David Tuveson and Hans Clevers and/or MICRODOSING Devices by Robert Langer

April 27, 2017 by 2012pharmaceutical

Pharmacotyping Pancreatic Cancer Patients in the Future: Two Approaches – ORGANOIDS by David Tuveson and Hans Clevers and/or MICRODOSING Devices by Robert Langer

Curator: Aviva Lev-Ari, PhD, RN

 

UPDATED on 4/5/2018

Featured video: Magical Bob

A fascination with magic leads Institute Professor Robert Langer to solve world problems using the marvels of chemical engineering.Watch Video

MIT News Office
March 27, 2018

http://news.mit.edu/2018/featured-video-magical-bob-langer-0327

 

This curation provides the resources for edification on Pharmacotyping Pancreatic Cancer Patients in the Future

 

  • Professor Hans Clevers at Clevers Group, Hubrecht University

https://www.hubrecht.eu/onderzoekers/clevers-group/

  • Prof. Robert Langer, MIT

http://web.mit.edu/langerlab/langer.html

Langer’s articles on Drug Delivery

https://scholar.google.com/scholar?q=Langer+on+Drug+Delivery&hl=en&as_sdt=0&as_vis=1&oi=scholart&sa=X&ved=0ahUKEwixsd2w88TTAhVG4iYKHRaIAvEQgQMIJDAA

  • Professor David Tuveson, Director of the Cancer Center at Cold Spring Harbor Laboratory
A MODEL FOR LIFE – Waging war against pancreatic cancer: an interview with David Tuveson
David Tuveson
Disease Models & Mechanisms 2017 10: 353-357; doi: 10.1242/dmm.029975

organoids, which I know you’re pretty involved in with Hans Clevers. What are your plans for organoids of pancreatic cancer?

Organoids are a really terrific model of a patient’s tumour that you generate from tissue that is either removed at the time of surgery or when they get a small needle biopsy. Culturing the tissue and observing an outgrowth of it is usually successful and when you have the cells, you can perform molecular diagnostics of any type. With a patient-derived organoid, you can sequence the exome and the RNA, and you can perform drug testing, which I call ‘pharmacotyping’, where you’re evaluating compounds that by themselves or in combination show potency against the cells. A major goal of our lab is to work towards being able to use organoids to choose therapies that will work for an individual patient – personalized medicine.

Organoids could be made moot by implantable microdevices for drug delivery into tumors, developed by Bob Langer. These devices are the size of a pencil lead and contain reservoirs that release microdoses of different drugs; the device can be injected into the tumor to deliver drugs, and can then be carefully dissected out and analyzed to gain insight into the sensitivity of cancer cells to different anticancer agents. Bob and I are kind of engaged in a friendly contest to see whether organoids or microdosing devices are going to come out on top. I suspect that both approaches will be important for pharmacotyping cancer patients in the future.

From the science side, we use organoids to discover things about pancreatic cancer. They’re great models, probably the best that I know of to rapidly discover new things about cancer because you can grow normal tissue as well as malignant tissue. So, from the same patient you can do a comparison easily to find out what’s different in the tumor. Organoids are crazy interesting, and when I see other people in the pancreatic cancer field I tell them, you should stop what you’re doing and work on these because it’s the faster way of studying this disease.

SOURCE
http://dmm.biologists.org/content/10/4/353

Other related articles on Pancreatic Cancer and Drug Delivery published in this Open Access Online Scientific Journal include the following:

 

Pancreatic Cancer: Articles of Note @PharmaceuticalIntelligence.com

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/05/26/pancreatic-cancer-articles-of-note-pharmaceuticalintelligence-com/

Keyword Search: “Pancreatic Cancer” – 275 Article Titles

https://pharmaceuticalintelligence.com/wp-admin/edit.php?s=Pancreatic+Cancer&post_status=all&post_type=post&action=-1&m=0&cat=0&paged=1&action2=-1

Keyword Search: Drug Delivery: 542 Articles Titles

https://pharmaceuticalintelligence.com/wp-admin/edit.php?s=Drug+Delivery&post_status=all&post_type=post&action=-1&m=0&cat=0&paged=1&action2=-1

Keyword Search: Personalized Medicine: 597 Article Titles

https://pharmaceuticalintelligence.com/wp-admin/edit.php?s=Personalized+Medicine&post_status=all&post_type=post&action=-1&m=0&cat=0&paged=1&action2=-1

  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

 

 

VOLUME TWO WILL BE AVAILABLE ON AMAZON.COM ON MAY 1, 2017

Posted in 3D Printing for Medical Application, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Circulating Tumor Cells (CTC), Drug Delivery Platform Technology, Drug Development Process, Drug Development using MultiOrgan Chip, Drug Development/Formulation using 3D Printing, Genomic Expression, Genomic Testing: Methodology for Diagnosis, Genomics Pharmacy, Molecular Genetics & Pharmaceutical, Organoids, Pancreatic cancer, Patient-centered Medicine, Personalized and Precision Medicine & Genomic Research, Tissue Engineering and Regenerative Medicine | Leave a Comment »

Artificial womb for survival of premature fetus

April 27, 2017 by Dr. Sudipta Saha

Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Babies born at or before 25 weeks have quite low survival outcomes, and in the US it is the leading cause of infant mortality and morbidity. Just a few weeks of extra ‘growing time’ can be the difference between severe health problems and a relatively healthy baby.

 

Researchers from The Children’s Hospital of Philadelphia (USA) Research Institute have shown it’s possible to nurture and protect a mammal in late stages of gestation inside an artificial womb; technology which could become a lifesaver for many premature human babies in just a few years.

 

The researchers took eight lambs between 105 to 120 days gestation (the physiological equivalent of 23 to 24 weeks in humans) and placed them inside the artificial womb. The artificial womb is a sealed and sterile bag filled with an electrolyte solution which acts like amniotic fluid in the uterus. The lamb’s own heart pumps the blood through the umbilical cord into a gas exchange machine outside the bag.

 

The artificial womb worked in this study and after just four weeks the lambs’ brains and lungs had matured like normal. They had also grown wool and could wiggle, open their eyes, and swallow. Although this study is looking incredibly promising but getting the research up to scratch for human babies still requires a big leap.

 

Nevertheless, if all goes well, the researchers hope to test the device on premature humans within three to five years. Potential therapeutic applications of this invention may include treatment of fetal growth retardation related to placental insufficiency or the salvage of preterm infants threatening to deliver after fetal intervention or fetal surgery.

 

The technology may also provide the opportunity to deliver infants affected by congenital malformations of the heart, lung and diaphragm for early correction or therapy before the institution of gas ventilation. Numerous applications related to fetal pharmacologic, stem cell or gene therapy could be facilitated by removing the possibility for maternal exposure and enabling direct delivery of therapeutic agents to the isolated fetus.

 

References:

 

https://www.nature.com/articles/ncomms15112

 

 

https://www.sciencealert.com/researchers-have-successfully-grown-premature-lambs-in-an-artificial-womb

 

http://www.npr.org/sections/health-shots/2017/04/25/525044286/scientists-create-artificial-womb-that-could-help-prematurely-born-babies

 

http://www.telegraph.co.uk/science/2017/04/25/artificial-womb-promises-boost-survival-premature-babies/

 

https://www.theguardian.com/science/2017/apr/25/artificial-womb-for-premature-babies-successful-in-animal-trials-biobag

 

http://www.theblaze.com/news/2017/04/25/new-artificial-womb-technology-could-keep-babies-born-prematurely-alive-and-healthy/

 

http://www.theverge.com/2017/4/25/15421734/artificial-womb-fetus-biobag-uterus-lamb-sheep-birth-premie-preterm-infant

 

http://www.abc.net.au/news/2017-04-26/artificial-womb-could-one-day-keep-premature-babies-alive/8472960

 

https://www.theatlantic.com/health/archive/2017/04/preemies-floating-in-fluid-filled-bags/524181/

 

http://www.independent.co.uk/news/health/artificial-womb-save-premature-babies-lives-scientists-create-childrens-hospital-philadelphia-nature-a7701546.html

 

https://www.cnet.com/news/artificial-womb-births-premature-lambs-human-infants/

 

https://science.slashdot.org/story/17/04/25/2035243/an-artificial-womb-successfully-grew-baby-sheep—-and-humans-could-be-next

 

http://newatlas.com/artificial-womb-premature-babies/49207/

 

https://www.geneticliteracyproject.org/2015/06/12/artificial-wombs-the-coming-era-of-motherless-births/

 

http://news.nationalgeographic.com/2017/04/artificial-womb-lambs-premature-babies-health-science/

 

https://motherboard.vice.com/en_us/article/artificial-womb-free-births-just-got-a-lot-more-real-cambridge-embryo-reproduction

 

http://www.disclose.tv/news/The_Artificial_Womb_Is_Born_Welcome_To_The_WORLD_Of_The_MATRIX/114199

 

 

Posted in Biological Networks, Biomedical Measurement Science, Cell Biology, Clinical & Translational, Developmental biology, Discovery process, Embryology, Experimental validation, Great Discoveries, Innovations, Reproductive Biology & Bio Instrumentation | Tagged , , , , , , | Leave a Comment »

LAUREATES 2017 – The Dan David Prize is a joint international corporation, endowed by the Dan David Foundation and headquartered at Tel Aviv University

April 26, 2017 by 2012pharmaceutical

LAUREATES 2017 – – The Dan David Prize is a joint international corporation, endowed by the Dan David Foundation and headquartered at Tel Aviv University

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #234: LAUREATES 2017 – The Dan David Prize is a joint international corporation, endowed by the Dan David Foundation and headquartered at Tel Aviv University. Published on 4/26/17

WordCloud Image Produced by Adam Tubman

THE PRIZE AND ITS SPIRIT

The Dan David Prize is a joint international corporation, endowed by the Dan David Foundation and headquartered at Tel Aviv University.

The Dan David Prize recognizes and encourages innovative and interdisciplinary research that cuts across traditional boundaries and paradigms. It aims to foster universal values of excellence, creativity, justice, democracy and progress and to promote the scientific, technological and humanistic achievements that advance and improve our world.

The Dan David Prize covers three time dimensions – Past, Present and Future – that represent realms of human achievement. Each year the International Board chooses one field within each time dimension. Following a review process by independent Review Commitees comprised of renowned scholars and professionals, the International Board then chooses the laureates for each field.

The Past refers to fields that expand knowledge of former times.
The Present recognizes achievements that shape and enrich society today.
The Future focuses on breakthroughs that hold great promise for improvement of our world.

Three prizes of one million US dollars each are granted annually in the fields chosen for the three time dimensions. The prizes are granted to individuals or institutions with proven, exceptional, distinct excellence in the sciences, arts, humanities, public service and business, that have made and continue to make an outstanding contribution to humanity on the basis of merit, without discrimination of gender, race, religion, nationality, or political affiliation.

The Dan David Pize laureates donate 10% of their prize money to post graduate students in their respective fields, thereby contributing to the community and fostering a new generation of scholars. It is also unique in its outreach efforts to the wider community. Since its inception, the Dan David Prize has embarked upon two exciting innitiatives:

  • The Dan David Prize, in conjunction with the Unit for Science Oriented Youth at Tel Aviv University has initiated the ‘Name Your Hero’ Essay Competition for High School Youth throughout Israel. High school students are encouraged to make a difference and present their choice of candidate and/or suggestions for fields, to the mutual benefit of the Dan David Prize and the students; the fields selected for a given year are influenced by the students’ input and the students’ scholarship and creative writing skills are advanced.
  • A Scholars Forum has been established comprised of Dan David Prize scholarship recipients worldwide doing research in the various fields selected since the inception of the Dan David Prize. This forum serves as a platform for Dan David Prize scholars to discuss research topics, present individual research and exchange ideas and suggestions

For a better understanding of the drive behind the creation of the Prize, press here for Mr. Dan David’s speech at the Inaugurational Ceremony of the Prize, on May 12th 2001.

PAST – ARCHAEOLOGY AND NATURAL SCIENCES

PROF. SVANTE PÄÄBO

PROF. SVANTE PÄÄBO
Max Planck Institute for Evolutionary Anthropology
GERMANY

PROF. DAVID REICH

PROF. DAVID REICH
Harvard Medical School
USA

PRESENT – LITERATURE

JAMAICA KINCAID

JAMAICA KINCAID
Author
USA

A. B. YEHOSHUA

A. B. YEHOSHUA
Author
ISRAEL

FUTURE – ASTRONOMY

PROF. NEIL GEHRELS (1952-2017)

PROF. NEIL GEHRELS (1952-2017)
NASA Goddard Space Flight Center
USA

PROF. SHRINIVAS KULKARNI

PROF. SHRINIVAS KULKARNI
California Institute of Technology
USA

PROF. ANDRZEJ UDALSKI

PROF. ANDRZEJ UDALSKI
Astronomical Observatory Warsaw University
POLAND

http://www.dandavidprize.org/laureates/2017?utm_source=newsletter_72&utm_medium=email&utm_campaign=may-is-upon-us-award-ceremony-and-events-dan-david-prize-monthly-news-april-2017

view online »

 

 Monthly News   Issue # 32  |   April, 2017

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

MAY IS UPON US

AWARD CEREMONY AND EVENTS WITH THE

2017 DAN DAVID PRIZE LAUREATES

 

 
 

DAN DAVID PRIZE AWARD CEREMONY

Sunday, May 21, 2017, 20:00

The Miriam and Adolfo Smolarz Auditorium

Tel Aviv University

By Invitation Only
 

 Monthly News   Issue # 32  |   April, 2017

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

MAY IS UPON US

AWARD CEREMONY AND EVENTS WITH THE

2017 DAN DAVID PRIZE LAUREATES

 

 

 

DAN DAVID PRIZE AWARD CEREMONY

Sunday, May 21, 2017, 20:00

The Miriam and Adolfo Smolarz Auditorium

Tel Aviv University

By Invitation Only

 

 Monthly News   Issue # 32  |   April, 2017

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

MAY IS UPON US

AWARD CEREMONY AND EVENTS WITH THE

2017 DAN DAVID PRIZE LAUREATES

 

 

 

DAN DAVID PRIZE AWARD CEREMONY

Sunday, May 21, 2017, 20:00

The Miriam and Adolfo Smolarz Auditorium

Tel Aviv University

By Invitation Only

 

 Monthly News   Issue # 32  |   April, 2017

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

MAY IS UPON US

AWARD CEREMONY AND EVENTS WITH THE

2017 DAN DAVID PRIZE LAUREATES

 

 

 

DAN DAVID PRIZE AWARD CEREMONY

Sunday, May 21, 2017, 20:00

The Miriam and Adolfo Smolarz Auditorium

Tel Aviv University

By Invitation Only

 

 Monthly News   Issue # 32  |   April, 2017

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

MAY IS UPON US

AWARD CEREMONY AND EVENTS WITH THE

2017 DAN DAVID PRIZE LAUREATES

 

 

 

DAN DAVID PRIZE AWARD CEREMONY

Sunday, May 21, 2017, 20:00

The Miriam and Adolfo Smolarz Auditorium

Tel Aviv University

By Invitation Only

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

 Monthly News   Issue # 32  |   April, 2017

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

MAY IS UPON US

AWARD CEREMONY AND EVENTS WITH THE

2017 DAN DAVID PRIZE LAUREATES

 

 

 

DAN DAVID PRIZE AWARD CEREMONY

Sunday, May 21, 2017, 20:00

The Miriam and Adolfo Smolarz Auditorium

Tel Aviv University

By Invitation Only

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

 Monthly News   Issue # 32  |   April, 2017

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

The Dan David Prize is an international prize which annually awards three prizes of US$ 1 million each for outstanding scientific, technological, cultural, and social achievements having an impact on our world. Each year fields are chosen within the three Time Dimensions – Past, Present and Future.

 

MAY IS UPON US

AWARD CEREMONY AND EVENTS WITH THE

2017 DAN DAVID PRIZE LAUREATES

 

 

 

DAN DAVID PRIZE AWARD CEREMONY

Sunday, May 21, 2017, 20:00

The Miriam and Adolfo Smolarz Auditorium

Tel Aviv University

By Invitation Only

Posted in Interviews with Scientific Leaders, The Dan David Prize | Leave a Comment »

Top Authors, by +5 years of e-Views, 1/29/2018, on pharmaceuticalintelligence.com

April 25, 2017 by 2012pharmaceutical

Top Authors, by +5 years of e-Views, 1/29/2018, on pharmaceuticalintelligence.com

UPDATED on 1/29/2018

Top Authors for all days ending 2018-01-29 (Summarized)

All Time

Author Views
Aviva Lev-Ari, PhD, RN [2012pharmaceutical] 352,153
Larry H Bernstein, MD, FCAP 252,504
Tilda Barliya, PhD 52,654
Stephen J Williams, PhD 45,882
Dror Nir, PhD 27,294
Dr. Sudipta Saha, PhD 24,413
Ritu Saxena, PhD 15,896
Demet Sag, Ph.D., CRA, GCP 14,574
Aviral Vatsa, PhD 8,353
Ziv Raviv, PhD 8,047
Gail S Thornton, PhD(c) 5,284
Zohi Sternberg, PhD 3,963
Danut Dragoi, PhD 3,416
Anamika Sarkar, PhD 3,346
Alan F. Kaul, PharmD., MS, MBA, FCCP 2,183
Prabod Kandala, PhD 2,176
Aashir Awan, PhD 1,983
Irina Robu, PhD 1,739
Justin D Pearlman, MD, PhD 1,609
Meg Baker, PhD 1,475
S. Chakrabarti, Ph.D. 728
Ed Kislauskis, PhD 648
David Orchard-Webb, PhD 565
Howard Donohue, PhD 548
Stuart Cantor, PhD 471
Marzan Khan, BSc 440
Evelina Cohn, PhD 390

 

Top Authors, by 5 years of e-Views, 4/25/2017, on pharmaceuticalintelligence.com

Reporter: Aviva Lev-Ari, PhD, RN

 

Top Authors for all days ending 2017-04-25 (Summarized)

All Time

4/30/2012 – 4/25/2017

Author

Views
Aviva Lev-Ari, PhD, RN 315,262
 

Larry H Bernnstein, MD, FCAP
220,787
Tilda Barliya, PhD 47,008
 

Stephen J Williams, PhD
39,704
Dror Nir, PhD
24,484
Sudipta Saha, PhD
22,253
Ritu Saxena, PhD
15,302
Demet Sag, Ph.D., CRA, GCP
12,982
Aviral Vatsa, PhD
8,082
Ziv Raviv, PhD
7,525
Zohi Sternberg, PhD
3,839
Anamika Sarkar, PhD, MBA
3,269
Gail S Thornton, MA, PhD(c)
2,885
Danut Dragoi, PhD
2,607
Prabodh Kandala, PhD
2,115
Alan F. Kaul, PharmD., MS, MBA, FCCP
2,057
Aashir Awan, PhD
1,841
Meg Baker, PhD
1,439
Justin D Pearlman, MD, PhD
1,429
Irina Robu, PhD
949
S. Chakrabarti, Ph.D. 622

 

 

Posted in LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management | Leave a Comment »

Tommy King Memorial Cardiovascular Symposium, St. Elizabeth’s Medical Center, Boston, May 20, 2017

April 24, 2017 by 2012pharmaceutical

Tommy King Memorial Cardiovascular Symposium

Reporter: Aviva Lev-Ari, PhD, RN

 

Saturday CEUs in Boston, May 20, 2017

St. Elizabeth’s Medical Center

Boston, MA

May 20

7:30am – 3pm

PROGRAM SCHEDULE & SESSIONS

07:30am | Registration & Continental Breakfast

08:00am | Hemodynamics; Faisal Khan, MD, St. Elizabeth’s Medical Center

09:00am | Radiation Protection; Satish Nair, PhD, F.X. Masse Associates

10:00am | Break & Exhibits

10:15am | Structural Heart – TAVR Updates and Watchman

Joseph Carrozza, MD, St. Elizabeth’s Medical Center

11:15am | Road to the Cath Lab — Triggers for STEMI Activation 

Lawrence Garcia, MD, St. Elizabeth’s Medical Center

12:15pm | Lunch

01:00pm | HF Program including Cardiomems

Lana Tsao, MD & Jaclyn Mayer, NP, St. Elizabeth’s Medical Center

02:00pm | Cath Lab Pharmacology

Mirembe Reed, Pharm.D, St. Elizabeth’s Medical Center

Register now »

SOURCE

From: <acvp@getresponse.com> on behalf of “Kurt, ACVP” <kurt@acp-online.org>

Reply-To: <kurt@acp-online.org>

Date: Monday, April 24, 2017 at 2:26 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: cardiovascular symposium in Boston, May 20

Posted in Aortic Valve: TAVR, TAVI vs Open Heart Surgery, Cancer Surgery of the Heart, Cardiac and Cardiovascular Surgical Procedures, Frontiers in Cardiology and Cardiovascular Disorders, PCI, Stents & Tools, Valves & Tools | Tagged | Leave a Comment »

« Newer Posts - Older Posts »